SCHEMBL4770833

SCHEMBL4770833

ClCCCNc1cccc(Cl)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 4/20 0.51
ICMT O60725 2/20 0.44
MAPT P10636 4/20 0.44
ALDH1A1 P00352 3/20 0.44
HTT P42858 2/20 0.44
MEN1 O00255 1/20 0.44
LMNA P02545 1/20 0.44
KMT2A Q03164 1/20 0.44
GAA P10253 1/20 0.44
CAMK2D Q13557 1/20 0.43
KDR P35968 3/20 0.43
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
EPHX1 P07099 3/20 0.42
CDK1 P06493 1/20 0.41
FGFR2 P21802 1/20 0.41
GSK3A P49840 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL4776594 0.98 EGFR (0.50) EGFRICMTMAPTALDH1A1HTT
SCHEMBL11115361 0.90 MAPT (0.54) EGFRICMTMAPTALDH1A1HTT
SCHEMBL10994687 0.88 EGFR (0.57) EGFRICMTMAPTALDH1A1HTT
SCHEMBL11527837 0.86 MAPT (0.56) EGFRICMTMAPTALDH1A1HTT
SCHEMBL11113758 0.85 ALDH1A1 (0.48) EGFRICMTMAPTALDH1A1HTT
SCHEMBL11114661 0.85 MAPT (0.65) ICMTMAPTALDH1A1HTTMEN1
SCHEMBL2920696 0.83 EPHX1 (0.59) EGFRMAPTALDH1A1KMT2AEPHX1
SCHEMBL4163471 0.83 MEN1 (0.47) EGFRICMTMAPTALDH1A1HTT
SCHEMBL4822806 0.83 CAMK2D (0.48) EGFRICMTMAPTALDH1A1HTT
SCHEMBL11115302 0.83 MAPT (0.52) EGFRICMTMAPTALDH1A1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101412692-B 1-(3-amino propyl) piperidine-4-aminoamide compounds, and pharmaceutical composition, preparation and use thereof SHANGHAI INST MATERIA MEDICA 2012-10-17 CN disclosed
CN-101412692-A 1-(3-amino propyl) piperidine-4-aminoamide compounds, and pharmaceutical composition, preparation and use thereof SHANGHAI INST MATERIA MEDICA (CN) 2009-04-22 CN disclosed
US-7348324-B2 Cyclic amine compounds as CCR5 antagonists TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-03-25 US disclosed
EP-1886994-A1 Cyclic amine compounds as CCR5 antagonists Takeda Pharmaceutical Company Limited (JP) 2008-02-13 EP disclosed
US-20030114443-A1 Cyclic amine compounds as CCR5 antagonists TOBIRA THERAPEUTICS, INC. 2003-06-19 US disclosed
US-6562978-B1 N-(3-(4-(4-(Aminocarbonyl)benzyl)-1-piperidinyl)propyl)-N-(3, 4-dichlorophenyl)-1-(methylsulfonyl)-4-piperidinecarboxamide or a salt thereof for treatment of AIDS TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) 2003-05-13 US disclosed
EP-0058868-B1 DERIVATIVES OF TETRAHYDROPYRIMIDINON, PROCESS FOR THEIR PREPARATION AND HERBICIDES CONTAINING THOSE DERIVATIVES AS ACTIVE PRODUCTS NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) 1984-04-11 EP disclosed
US-4402731-A Herbicidally active novel substituted tetrahydropyrimidinones NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) 1983-09-06 US disclosed
EP-0058868-A1 Derivatives of tetrahydropyrimidinon, process for their preparation and herbicides containing those derivatives as active products NIHON TOKUSHU NOYAKU SEIZO K.K. (JP) 1982-09-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030114443-A1 Cyclic amine compounds as CCR5 antagonists CCR5, CCR1, CCR3 EGFR 2100/4885ICMT 1232/4885MAPT 4492/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.